Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Time-in-Human (FTiH), Phase I Trial to Evaluate the Safety, Cellular Kinetics, and Efficacy of A-CAR032, in Adult Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT07344311 is registered in ClinicalTrials.gov with Shanghai AbelZeta Ltd. as lead sponsor.

NCT NCT07344311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07344311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Time-in-Human (FTiH), Phase I Trial to Evaluate the Safety, Cellular Kinetics, and Efficacy of A-CAR032, in Adult Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Shanghai AbelZeta Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 13, 2026
Completion date
January 31, 2042
Enrollment
27 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, prostate cancer